Kt Corporation ADR Aktie
Finanztrends
Deine Einschätzung
Kt Corporation ADR Aktie
Abwärts geht es heute für die Kt Corporation ADR Aktie mit einem Verlust von -1,21 %.
Was spricht für und gegen Kt Corporation ADR in den nächsten Jahren?
Pro
?
M****
?
M************
?
W******* i* V********
Kontra
?
U****************
?
A****************
?
L*********** I********** f** d** n******* J****
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Kt Corporation ADR im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Kt Corporation ADR | -1,21 % | 5,77 % | 9,27 % | -5,71 % | 4,43 % | 48,65 % | 29,92 % |
| Freenet AG | 0,00 % | -1,57 % | -0,17 % | -15,66 % | -19,32 % | 10,39 % | 18,29 % |
| Philippine Long Distance Telephone Company ADR | -1,20 % | -0,60 % | 0,61 % | -13,54 % | -7,78 % | -17,82 % | -17,82 % |
| Telekom Austria AG | 1,38 % | 2,19 % | 2,40 % | 8,23 % | 14,25 % | 53,36 % | 35,71 % |
Kommentare
News
Kymera Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Kymera Therapeutics, Inc.? Here are five stocks we like better.
- KT-621 atopic dermatitis trial enrollment is complete about six months ahead of schedule, with top-line
Kymera's CEO Sold $6 Million in Stock After a 170% Run
Chief Executive Officer Nello Mainolfi sold 50,000 shares of Kymera Therapeutics (NASDAQ:KYMR) on July 7, 2026, for total proceeds of about $6.0 million, according to an SEC Form 4 filing.
Kymera
Why Kymera Therapeutics Stock Popped This Week
This week was an eventful one for Kymera Therapeutics (NASDAQ: KYMR). The clinical-stage biotech announced the early completion of enrollment in an important clinical trial. It also earned a clutch